Advertisement
| ascvd risk and statin therapy: Coronary Primary Prevention Trial , 1984 |
| ascvd risk and statin therapy: Preventive Cardiology: A Practical Approach, Second Edition Nathan D. Wong, Henry Black, Julius M. Gardin, 2005 PREVENTIVE CARDIOLOGY is the premier source of clinically relevant information on the prevention of coronary heart disease. Thoroughly updated by international experts, the book discusses screening, risk factors, prevention in special populations, and primary and secondary prevention in the context of the daily practice of medicine. PREVENTIVE CARDIOLOGY is a must have for cardiologists and primary care physicians. Review of the first edition: Excellent...Structured in a way that invites the reader to use it as a comprehensive reference...The combination of theory and guidelines with a practical approach to the patient at risk for cardiovascular diseases is a strength. The New England Journal of Medicine |
| ascvd risk and statin therapy: Statin-Associated Muscle Symptoms Paul D. Thompson, Beth A. Taylor, 2020-01-25 This book provides an overview of statin-associated muscle symptoms (SAMS) from clinical presentation to treatment and possible metabolic causes. It examines the risk factors, presentations, diagnosis and differential diagnosis, clinical management, and financial costs of SAMS. The book also highlights patients’ perspectives on SAMS such as the psychosocial, emotional, and societal factors influencing their perceptions and experiences. Finally, the book presents the results of observational and clinical trials on the prevalence of SAMS, clinical trials for treatments, and potential future research approaches for improving the understanding and treatment of SAMS. A key addition to the Contemporary Cardiology series, Statin-Associated Muscle Symptoms is an essential resource for physicians, medical students, residents, fellows, and allied health professionals in cardiology, endocrinology, pharmacotherapy, primary care, and health promotion and disease prevention. |
| ascvd risk and statin therapy: Management of Dyslipidemia Wilbert S. Aronow, 2021-07-21 Dyslipidemia is a major risk factor for cardiovascular events, cardiovascular mortality, and all-cause mortality. The earlier in life dyslipidemia is treated, the better the prognosis. The current book is an excellent one on dyslipidemia written by experts on this topic. This book includes 12 chapters including 5 on lipids, 4 on hypercholesterolemia in children, and 3 on the treatment of dyslipidemia. This book should be read by all health care professionals taking care of patients, including pediatricians since atherosclerotic cardiovascular disease begins in childhood. |
| ascvd risk and statin therapy: Lipid Management Hussein Yassine, 2015-03-03 This timely, concise title provides an important update on clinical lipid management. Using information from recent clinical trials and in special populations, the book begins by offering an easy-to-read overview of LDL, HDL, and triglyceride metabolism and the genetics of lipid disorders. The link between inflammation and lipids, and how this relates to atherosclerosis development, is also addressed, as are the measures of subclinical atherosclerosis in patients with abnormal lipid levels. Lipid abnormalities in children, with a particular focus on vulnerable populations (with an emphasis on ethnicity and childhood obesity), are covered. The treatment goals and approaches for managing lipids in the clinic are thoroughly discussed, emphasizing the important role of statin use and addressing controversies of lipid management in special populations such as heart failure, end stage kidney disease and fatty liver disease. Of special note, an important update on how new HIV medications impact lipid levels is provided. In all, Lipid Management: From Basics to Clinic, is an invaluable, handy resource for understanding changes in lipids in different populations and for sharpening the clinical approach to managing complicated lipid cases. |
| ascvd risk and statin therapy: Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult Treatment Panel II). National Cholesterol Education Program (U.S.). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 1993 |
| ascvd risk and statin therapy: Secondhand Smoke Exposure and Cardiovascular Effects Institute of Medicine, Board on Population Health and Public Health Practice, Committee on Secondhand Smoke Exposure and Acute Coronary Events, 2010-02-21 Data suggest that exposure to secondhand smoke can result in heart disease in nonsmoking adults. Recently, progress has been made in reducing involuntary exposure to secondhand smoke through legislation banning smoking in workplaces, restaurants, and other public places. The effect of legislation to ban smoking and its effects on the cardiovascular health of nonsmoking adults, however, remains a question. Secondhand Smoke Exposure and Cardiovascular Effects reviews available scientific literature to assess the relationship between secondhand smoke exposure and acute coronary events. The authors, experts in secondhand smoke exposure and toxicology, clinical cardiology, epidemiology, and statistics, find that there is about a 25 to 30 percent increase in the risk of coronary heart disease from exposure to secondhand smoke. Their findings agree with the 2006 Surgeon General's Report conclusion that there are increased risks of coronary heart disease morbidity and mortality among men and women exposed to secondhand smoke. However, the authors note that the evidence for determining the magnitude of the relationship between chronic secondhand smoke exposure and coronary heart disease is not very strong. Public health professionals will rely upon Secondhand Smoke Exposure and Cardiovascular Effects for its survey of critical epidemiological studies on the effects of smoking bans and evidence of links between secondhand smoke exposure and cardiovascular events, as well as its findings and recommendations. |
| ascvd risk and statin therapy: The Truth About Statins Barbara H. Roberts, 2012-04-24 Discusses the uses, misuses, dangers, and benefits of statin drugs, counseling patients on how to make informed choices about side effects and lifestyle changes that can promote cardiovascular health. |
| ascvd risk and statin therapy: Decision Making in Health and Medicine M. G. Myriam Hunink, Milton C. Weinstein, Eve Wittenberg, 2014-10-16 A guide for everyone involved in medical decision making to plot a clear course through complex and conflicting benefits and risks. |
| ascvd risk and statin therapy: Pericardial Disease J. Soler-Soler, G. Permanyer, J. Sagristà-Sauleda, 2012-12-06 In November 1986, I was invited to attend a symposium held in Barcelona on Diseases of the Pericardium. The course was directed by Dr. J. Soler-Soler, director of Cardiology at Hospital General Vall d'Hebron in Barcelona. During my brief but delightful visit to this institution, my appreciation of the depth and breadth of study into pericardial diseases, carried out by Dr. Soler and his group, grew into the conviction that these clinical investigators have accumulated a wealth of information concerning pericardial diseases, and that investigators and clinicians practicing in English speaking countries would greatly profit from ready access to the results of the clinical investiga tions into pericardial disease carried out in Barcelona. The proceedings of the Barcelona conference were published in a beauti fully executed volume in the Spanish language edited by Dr. Soler and pro duced by Ediciones Doyma. Because I believe that this work should be brought to the attention of the English speaking scientific and clinical com munities, I encouraged Dr. Soler to have the book translated into English. I knew that this task could be accomplished and that the book would be trans lated into good English without change of its content. My confidence was based upon a translation of my own book, The Pericardium, into Spanish undertaken by Dr. Permanyer, who is a contributor and co-editor of the pre sent volume. |
| ascvd risk and statin therapy: Antiplatelet and Anticoagulation Therapy Albert Ferro, David A. Garcia, 2012-10-13 This title will be presented as highly practical information pn pharmaceutical antiplatelet and anticoagulation therapy, written in a quick-access, no-nonsense format. The emphasis will be on a just-the-facts clinical approach, heavy on tabular material, light on dense prose. The involvement of the ISCP will ensure that the best quality contributors will be involved and establish a consistent approach to each topic in the series. Each volume is designed to be between 120 and 250 pages containing practical illustrations and designed to improve understand and practical usage of cardiovascular drugs in specific clinical areas. |
| ascvd risk and statin therapy: Clinical Practice Guidelines We Can Trust Institute of Medicine, Board on Health Care Services, Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, 2011-06-16 Advances in medical, biomedical and health services research have reduced the level of uncertainty in clinical practice. Clinical practice guidelines (CPGs) complement this progress by establishing standards of care backed by strong scientific evidence. CPGs are statements that include recommendations intended to optimize patient care. These statements are informed by a systematic review of evidence and an assessment of the benefits and costs of alternative care options. Clinical Practice Guidelines We Can Trust examines the current state of clinical practice guidelines and how they can be improved to enhance healthcare quality and patient outcomes. Clinical practice guidelines now are ubiquitous in our healthcare system. The Guidelines International Network (GIN) database currently lists more than 3,700 guidelines from 39 countries. Developing guidelines presents a number of challenges including lack of transparent methodological practices, difficulty reconciling conflicting guidelines, and conflicts of interest. Clinical Practice Guidelines We Can Trust explores questions surrounding the quality of CPG development processes and the establishment of standards. It proposes eight standards for developing trustworthy clinical practice guidelines emphasizing transparency; management of conflict of interest ; systematic review-guideline development intersection; establishing evidence foundations for and rating strength of guideline recommendations; articulation of recommendations; external review; and updating. Clinical Practice Guidelines We Can Trust shows how clinical practice guidelines can enhance clinician and patient decision-making by translating complex scientific research findings into recommendations for clinical practice that are relevant to the individual patient encounter, instead of implementing a one size fits all approach to patient care. This book contains information directly related to the work of the Agency for Healthcare Research and Quality (AHRQ), as well as various Congressional staff and policymakers. It is a vital resource for medical specialty societies, disease advocacy groups, health professionals, private and international organizations that develop or use clinical practice guidelines, consumers, clinicians, and payers. |
| ascvd risk and statin therapy: Guideline World Health Organization, 2015-12-15 This guideline provides the first global, evidence-informed recommendations on the consumption of potassium to reduce NCDs in most adults and children which WHO had developed. The recommendations in this guideline can be used by policy-makers, technical and program planners in the government and various organizations involved in the design, implementation and scaling-up of nutrition actions for public health and prevention of NCDs, to assess current potassium intake levels relative to a benchmark and develop measures to increase potassium intake, where necessary, through public health interventions including, but not limited to, food and product labelling, consumer education, and the establishment of food-based dietary guidelines (FBDG). The guideline should be used in conjunction with sodium and other nutrient guidelines to develop and guide national policies and public health nutrition programs. |
| ascvd risk and statin therapy: Clinical Lipidology Christie M. Ballantyne, 2009-01-01 Clinical Lipidology, a companion to Braunwald's Heart Disease, is designed to guide you through the ever-changing therapeutic management of patients with high cholesterol levels. From basic science to pathogenesis of atherothrombotic disease, to risk assessment and the latest therapy options, this medical reference book offers unparalleled coverage and expert guidance on lipidology in a straightforward, accessible, and user-friendly style. Get authoritative guidance from some of the foremost experts in the field. Easily access key content with help from treatment algorithms. Access options and evidence-based solutions for every type of patient scenario, as well as the latest clinical guidelines and clinically relevant evidence on risk assessment, special patient populations, and therapy, including recently approved and experimental therapies. Remain at the forefront of the cardiology field with up-to-date chapters on treatment guidelines; diet, exercise, and weight loss; pharmacologic therapies such as statins, omega-3 fatty acids, and combination therapy; evolving targets of therapy such as PCSK9 inhibition, CETP inhibition, and inflammation Prepare for special patient populations such as children and adolescents; women and the elderly; transplant recipients; HIV patients; and those with chronic renal disease, familial hypercholesterolemia, other severe hypercholesterolemias, diabetes, or other metabolic syndromes. Take advantage of a format that follows that of the well-known and internationally recognized Braunwald's Heart Disease. Expert Consult eBook version included with purchase. |
| ascvd risk and statin therapy: Trends in Elevated Triglyceride in Adults: United States, 2001-2012 Margaret D. Carroll, Brian K. Kit, David A. Lacher, 2015 |
| ascvd risk and statin therapy: Drug Treatment of Hyperlipidemia B. Rifkind, 1991-05-20 Originally published in 1991, ' Drugs Treatment of Hyperlipidemia' is a collection of essays that include studies on lipid metabolism, diagnosis of lipoprotein disorders, detection and treatment of dyslipoporteinemia and trials of lipid lowering drugs amongst its topics |
| ascvd risk and statin therapy: OECD Health Policy Studies Cardiovascular Disease and Diabetes: Policies for Better Health and Quality of Care OECD, 2015-06-17 This report examines how countries perform in their ability to prevent, manage and treat cardiovascular disease (CVD) and diabetes. |
| ascvd risk and statin therapy: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults (U.S.), 1998 Of evidence-based recommendations -- Introduction -- Overweight and obesity: background -- Examination of randomized controlled trial evidence -- Treatment guidelines -- Summary of recommendations -- Future research. |
| ascvd risk and statin therapy: Cardiovascular Diseases and Depression Bernhard T. Baune, Phillip J. Tully, 2016-08-01 The world is witnessing a burgeoning global epidemic of chronic cerebro- and cardiovascular disease and depression disorders. The reader will find this comprehensive book to be a long-needed, up-to-date knowledge base on these increasingly recognized comorbid conditions that have long-term consequences for individual function and well-being and society in general. This comprehensive book outlines the complex and bidirectional relationship between various types of depression and cerebro- and cardiovascular diseases. It is written by a range of experts in the field, including psychiatrists, cardiologists, neuroscientists, psychologists, and epidemiologists, with the aim of presenting and discussing the most recent evidence on the pathophysiology, neurobiology, and clinical presentation of these common and disabling comorbid conditions and the available pharmacological, psychological, and behavioral interventions. By elucidating the underlying clinical and neurobiological mechanisms in the brain and the rich interplay between the body and the brain biology, the book brings together the latest knowledge of this overlapping area in Psychiatry and Cardiology. The clear descriptions of evidence-based approaches to clinical treatment ensure that it will serve as both an up-to-date overview and a future guide for practicing clinicians and graduate students. |
| ascvd risk and statin therapy: Pharmacotherapy Casebook Terry L. Schwinghammer, 2005 This casebook is designed to help students develop the skills required to identify and resolve drug therapy problems through the use of patient case studies. |
| ascvd risk and statin therapy: ASPC Manual of Preventive Cardiology Ezra A. Amsterdam, Nathan Wong, Ezra Amsterdam, MD, Roger Blumenthal, MD, FACC, FAHA, 2014-10-23 Endorsed by the American Society for Preventive Cardiology, this highly practical resource focuses on the application of current guidelines and practice standards in the clinical management of cardiovascular risk factors. The Manual presents concise descriptions of each major cardiovascular risk factor, and practical, to-the-point discussions of current best practices in clinical management. In addition, the Manual includes chapters on peripheral arterial disease, stroke, smoking, contemporary cardiovascular imaging, heart failure, metabolic syndrome, thrombosis, nutrition, special populations, novel risk factors, and psychosocial stress. Throughout the Manual, recommendations are based on the most recent prevention guidelines of the American College of Cardiology and American Heart Association, including those on Risk Assessment, Lifestyle Recommendations, Blood Cholesterol, and Obesity, as well as the new guidelines on Hypertension. Chapter authors are recognized leaders in each area of practice, and special efforts have been made by the authors and editors to ensure that the content of all chapters is as up-to-date as possible. Key Features: Presents a highly practical focus on the application of current guidelines and practice standards regarding cardiovascular risk factors Recommendations based on the most recent prevention guidelines Authored by recognized leaders in the field Covers all major cardiovascular risk factors, key methodologies in risk assessment, and special issues regarding specific patient populations |
| ascvd risk and statin therapy: Lipids and Atherosclerosis Chris J. Packard, Daniel J. Rader, 2005-09-08 New discoveries in genetics, molecular, and cell biology are not only enhancing our understanding of the etiology and progression of disease, but are finding applications in the development of new drugs or the implementation of new kinds of therapy. This book provides an in-depth review of emerging areas in biomedical research at the interface of s |
| ascvd risk and statin therapy: Prevalence of Uncontrolled Risk Factors for Cardiovascular Disease Cheryl D. Fryar, Te-Ching Chen, Xianfen Li, 2012 |
| ascvd risk and statin therapy: Stroke Genetics Hugh S. Markus, 2003 Stroke is a major cause of death and the major cause of adult neurological disability in most of the world. Despite its importance on a population basis, research into the genetics of stroke has lagged behind that of many other disorders. However, the situation is now changing. An increasing number of single gene disorders causing stroke are being described, and there is growing evidence that polygenic factors are important in the risk of apparently sporadic stroke. Stroke Genetics provides an up-to-date review of the area, suitable for clinicians treating stroke patients, and both clinical and non-clinical researchers in the field of cerebrovascular disease. The full range of monogenic stroke disorders causing cerebrovascular disease, including ischaemic stroke, intracerebral haemorrhage, aneurysms and arteriovenous malformations, are covered. For each, clinical features, diagnosis, and genetics are described. Increasing evidence suggest that genetic factors are also important for the much more common multifactorial stroke; this evidence is reviewed along with the results of genetic studies in this area. Optimal and novel strategies for investigating multifactorial stroke, including the use of intermediate phenotypes such as intima-media thickness and MRI detected small vessel disease are reviewed. The book concludes by describing a practical approach to investigating patients with stroke for underlying genetic disorders. Also included is a list of useful websites. |
| ascvd risk and statin therapy: Asymptomatic Atherosclerosis Morteza Naghavi, 2010-07-01 Despite recent advances in the diagnosis and treatment of symptomatic atherosclerosis, available traditional screening methods for early detection and treatment of asymptomatic coronary artery disease are grossly insufficient and fail to identify the majority of victims prior to the onset of a life-threatening event. In Asymptomatic Atherosclerosis: Pathophysiology, Detection and Treatment, Dr. Morteza Naghavi and leading authorities from the Society for Heart Attack Prevention and Eradication (SHAPE) present a new paradigm for the screening and primary prevention of asymptomatic atherosclerosis. The text focuses on accurate, yet underutilized, measures of subclinical atherosclerosis, notably coronary artery calcium scanning and carotid intima-media thickness measurement. The authors introduce a comprehensive approach to identifying the vulnerable patients (asymptomatic individuals at risk of a near future adverse event). Additional chapters discuss future directions towards containing the epidemic of atherosclerotic cardiovascular disease using innovative solutions such as preemptive interventional therapies (bioabsorbable stents) for stabilization of vulnerable atherosclerotic plaques, mass unconditional Polypill therapy for population-based risk reduction, and ultimately vaccination strategies to prevent the development of atherosclerosis. Up-to-date and authoritative, Asymptomatic Atherosclerosis: Pathophysiology, Detection, and Treatment is a must-have for any cardiologist or primary care physician who wishes to practice modern preventive cardiology and manage the increasing number of asymptomatic atherosclerotic patients. Outlines more accurate measures of risk (coronary artery calcium and carotid intima-media thickness) than traditional risk factors (total cholesterol, LDL cholesterol, HDL cholesterol) Presents new multipronged strategies to aid in the early detection and treatment of high risk asymptomatic patients |
| ascvd risk and statin therapy: Stroke-Vascular Diseases W.Wolfgang Fleischhacker, David J. Brooks, 2002-11-07 Atherosclerosis, the underlying cause of heart attacks, strokes and peripheral vascular disease, is one of the major killers in the world. By 2020 WHO statistics indicate that it will be the most common cause of morbidity and mortality in both the industrialised world and the underdeveloped world. The disease develops slowly over many years in the innermost layer of large and medium-sized arteries (Fig. 1) (Scott, 1995; Ross, 1999; Naumova and Scott, 2000; Glass and Witztum, 2001; Libby, 2001). It does not usually become manifest before the fourth of fifth decade, but then often strikes with devas tating suddenness. Fifty per cent of individuals still die (25 per cent immedi ately) from their first heart attack; and morbidity from coronary heart disease and stroke is very significant. The disease has a profound impact on health care services and on industrial economies. The lesions of atherosclerosis Autopsy studies show that in humans atherosclerosis begins in the first and second decade of life. A similar disease can be produced in experimental animals, where diet and genetics can be manipulated to produce identical lesions. The earliest lesions are fatty streaks. These consist of an accumulation of lipid-engorged macrophages (foam cells) and T and B lymphocytes in the arterial intima. With time, the fatty streaks progress to intermediate lesions, composed of foam cells and smooth muscle cells. |
| ascvd risk and statin therapy: Dyslipidemia: A Clinical Approach Merle Myerson, 2018-02-08 An ideal reference for practitioners and health care professionals who care for patients with abnormal lipids, Dyslipidemia: A Clinical Approach provides clinically relevant, user-friendly information on all aspects of this rapidly evolving field. In addition to concise yet in-depth coverage of key topics, chapters include background information, evidence from the literature, and author commentary on conflicting or debated recommendations. Written by respected leaders in cardiology, nutrition, pharmacology, endocrinology and diabetes, pediatrics, nursing, obstetrics and gynecology, and lipidology, this one-stop reference is an excellent resource for helping patients lower the burden of atherosclerotic lipid particles and reduce the risk for cardiovascular disease. |
| ascvd risk and statin therapy: Honolulu Heart Program Abraham Kagan, 1996-08-01 The Director of this study, Abraham Kagan, has comprehensively summarized the design and main finndings of the study in this book. The Honolulu Heart Program compared and contrasted ethnic Japanese men living in different cultural environments--Honolulu and mainland Japan--assessed their relative risk factors. The study supported many of the existing views on risk factors but also showed suprising trends. One of the trends shows moderate alcohol consumption is a preventative factor. In recent years the risk factors for cardiovascular diseases have become common knowledge. The recently completed Honolulu Heart Program is the largest targeted study to evaluate scientifically such risk factors. |
| ascvd risk and statin therapy: Clinical Epidemiology Alvan R. Feinstein, 1985 |
| ascvd risk and statin therapy: Coronaries and Cholesterol Walter John Cliff, G. I. Schoefl, 1989 |
| ascvd risk and statin therapy: Exploring the Biological Contributions to Human Health Institute of Medicine, Board on Health Sciences Policy, Committee on Understanding the Biology of Sex and Gender Differences, 2001-07-02 It's obvious why only men develop prostate cancer and why only women get ovarian cancer. But it is not obvious why women are more likely to recover language ability after a stroke than men or why women are more apt to develop autoimmune diseases such as lupus. Sex differences in health throughout the lifespan have been documented. Exploring the Biological Contributions to Human Health begins to snap the pieces of the puzzle into place so that this knowledge can be used to improve health for both sexes. From behavior and cognition to metabolism and response to chemicals and infectious organisms, this book explores the health impact of sex (being male or female, according to reproductive organs and chromosomes) and gender (one's sense of self as male or female in society). Exploring the Biological Contributions to Human Health discusses basic biochemical differences in the cells of males and females and health variability between the sexes from conception throughout life. The book identifies key research needs and opportunities and addresses barriers to research. Exploring the Biological Contributions to Human Health will be important to health policy makers, basic, applied, and clinical researchers, educators, providers, and journalists-while being very accessible to interested lay readers. |
| ascvd risk and statin therapy: Evidence-Based Hypertension Cynthia Mulrow, 2001-03-30 This is a practice-oriented textbook for primary care clinicians on managing hypertension. The book summarizes all available research evidence that clinicians need to care for hypertensive patients. It also interprets the data to make it meaningful and useful and that advises readers about the quality and quantity of the evidence supporting the findings. Some of the main topics addressed in this book include taking accurate blood pressure measurements, determining the effectiveness of various blood pressure treatments, controlling difficult to control blood pressure, and treating hypertensive patients with other comorbid conditions. |
| ascvd risk and statin therapy: Overdosed America John Abramson, 2005-06-14 Using the examples of Vioxx, Celebrex, cholesterol-lowering statin drugs, and anti-depressants, Overdo$ed America shows that at the heart of the current crisis in American medicine lies the commercialization of medical knowledge itself. Drawing on his background in statistics, epidemiology, and health policy, John Abramson, M.D., an award-winning family doctor on the clinical faculty at Harvard Medical School, reveals the ways in which the drug companies have misrepresented statistical evidence, misled doctors, and compromised our health. The good news is that the best scientific evidence shows that reclaiming responsibility for your own health is often far more effective than taking the latest blockbuster drug. You -- and your doctor -- will be stunned by this unflinching exposé of American medicine. |
| ascvd risk and statin therapy: Coronary Angioscopy Kyoichi Mizuno, Masamichi Takano, 2015-07-03 This book presents a thorough review of coronary angioscopy, ranging from instructions on its use to the latest advances. Starting with the structure and fundamental principles of angioscopy, it shows readers how to apply the image to comprehensive care of coronary-artery patients. Plentiful color photos and illustrations will enable readers to investigate and classify plaques and thrombi and to evaluate coronary stent- and drug-based therapies. The authors are leading researchers on angioscopy. This book offers the perfect guide not only for new clinicians but also for cardiologists who have already adopted this technique for medical examination and treatment. Angioscopy is a unique medical technique for visualizing the interior of blood vessels and helps physicians not only to diagnose the pathology but also to measure the effectiveness of Percutaneous coronary intervention (PCI) or antiarteriosclerotic drugs. Furthermore, the recently developed molecular angioscopy approach allows us to observe Low-density lipoprotein (LDL) oxide, collagen, and macrophages, and is rapidly growing in importance. |
| ascvd risk and statin therapy: Textbook of Diabetes Richard I. G. Holt, Clive Cockram, Allan Flyvbjerg, Barry J. Goldstein, 2017-03-06 Now in its fifth edition, the Textbook of Diabetes has established itself as the modern, well-illustrated, international guide to diabetes. Sensibly organized and easy to navigate, with exceptional illustrations, the Textbook hosts an unrivalled blend of clinical and scientific content. Highly-experienced editors from across the globe assemble an outstanding set of international contributors who provide insight on new developments in diabetes care and information on the latest treatment modalities used around the world. The fifth edition features an array of brand new chapters, on topics including: Ischaemic Heart Disease Glucagon in Islet Regulation Microbiome and Diabetes Diabetes and Non-Alcoholic Fatty Liver Disease Diabetes and Cancer End of Life Care in Diabetes as well as a new section on Psychosocial aspects of diabetes. In addition, all existing chapters are fully revised with the very latest developments, including the most recent guidelines from the ADA, EASD, DUK and NICE. Includes free access to the Wiley Digital Edition providing search across the book, the full reference list with web links, illustrations and photographs, and post-publication updates Via the companion website, readers can access a host of additional online materials such as: 200 interactive MCQ's to allow readers to self-assess their clinical knowledge every figure from the book, available to download into presentations fully searchable chapter pdfs Once again, Textbook of Diabetes provides endocrinologists and diabetologists with a fresh, comprehensive and multi-media clinical resource to consult time and time again. |
| ascvd risk and statin therapy: Nutrition Guide for Clinicians Neal D. Barnard, Rick Weissinger, MS, Brent J. Jaster, MD, 2009 Designed by medical professionals, this manual is a comprehensive, portable medical reference that covers nearly one hundred diseases and conditions, including risk factors, diagnoses, and typical treatments. Most importantly, it provides the latest evidence-based information on nutrition's role in prevention and treatment. |
| ascvd risk and statin therapy: Type 2 Diabetes Anca Pantea Stoian, 2021-09-22 Diabetes mellitus is a metabolic disease characterized by chronic high blood glucose levels. Of the various types of diabetes, type 2 diabetes is increasing in prevalence due to obesity, aging, sedentarism, and other factors. This book presents a novel approach to preventing and treating type 2 diabetes. Chapters cover such topics as diagnosis, pathogenesis, management, lifestyle and nutritional intervention, and systems to support early diagnosis and prevention of prediabetes. |
| ascvd risk and statin therapy: Highlights of the Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents National Cholesterol Education Program (U.S.). Expert Panel on Blood Cholesterol Levels in Children and Adolescents, 1991 |
| ascvd risk and statin therapy: Lipids and Cardiovascular Disease , 1990 |
| ascvd risk and statin therapy: Harrison's Cardiovascular Medicine Joseph Loscalzo, 2010-06-04 Market: cardiologists and fellows (26,000), second year medical students (18,000/year), internal medicine residents (23,000); internists (75,000), family practice clinicians and residents (55,000); nurse practitioners (50,000), physician assistants (40,000) |
Low-Dose Colchicine Approved for CVD: Now What? - Medscape
Jun 22, 2023 · The recent US approval of a new low dose of colchicine 0.5 mg (Lodoco; Agepha Pharma) with a broad indication for use in atherosclerotic cardiovascular disease (ASCVD) …
AACE Publishes Guideline on Drug Management of Dyslipidemia
Feb 13, 2025 · It includes 13 evidence-based recommendations for the pharmacologic management of adults with dyslipidemia, focused on patient-important outcomes of ASCVD …
Less TV Time Cuts ASCVD Risk Despite Genetic Risk for T2D
Mar 20, 2025 · The 10-year absolute risk for ASCVD was lower in individuals with high T2D genetic risk who watched ≤ 1 hour of television daily than in those with low T2D genetic risk …
Good Performance for Universal CVD Risk Prediction Model
Feb 12, 2024 · A universal cardiovascular disease (CVD) prediction tool performs well in patients with and without atherosclerotic CVD (ASCVD), a new study showed, suggesting this model …
CHIP Tied to HFpEF and ASCVD: What’s the Link? - Medscape
Feb 2, 2024 · First described as a cancer risk factor, growing evidence links age-related clonal hematopoiesis of indeterminate potential (CHIP) to cardiovascular disease.
Cardiovascular Risk Calculators Fail Some Patients With HIV
Feb 24, 2025 · A common CV risk factor calculator for patients with HIV underestimates risk for Black patients and women, while risk for those in low-income countries is overestimated.
Evidence Builds to Support Colchicine in Treating ASCVD
May 6, 2024 · Colchicine, a legacy drug that received a new indication in 2023 for cardiovascular disease, can treat arterial inflammation after a heart attack, a principal investigator of clinical …
Risk-Calculator Flaws Not Explained by Statin Use - Medscape
Oct 7, 2014 · In an attempt to understand why the WHS cohort had a lower 10-year risk of ASCVD than that using the ACC/AHA risk calculator, researchers asked whether patients starting …
LDL Not the Primary Culprit in ASCVD? - Medscape
Dec 14, 2020 · LDL cholesterol has been seen as the main offender in ASCVD, but new studies implicate other lipids, including so-called "remnant" cholesterol. An editorial, however, urges …
Statin Use Remains Low for At-Risk Patients - Medscape
Dec 4, 2023 · Expanded prescribing guidelines have not boosted statin use among patients who are at risk for atherosclerotic cardiovascular disease.
Low-Dose Colchicine Approved for CVD: Now What? - Medscape
Jun 22, 2023 · The recent US approval of a new low dose of colchicine 0.5 mg (Lodoco; Agepha Pharma) with a broad indication for use in atherosclerotic cardiovascular disease (ASCVD) …
AACE Publishes Guideline on Drug Management of Dyslipidemia
Feb 13, 2025 · It includes 13 evidence-based recommendations for the pharmacologic management of adults with dyslipidemia, focused on patient-important outcomes of ASCVD …
Less TV Time Cuts ASCVD Risk Despite Genetic Risk for T2D
Mar 20, 2025 · The 10-year absolute risk for ASCVD was lower in individuals with high T2D genetic risk who watched ≤ 1 hour of television daily than in those with low T2D genetic risk …
Good Performance for Universal CVD Risk Prediction Model
Feb 12, 2024 · A universal cardiovascular disease (CVD) prediction tool performs well in patients with and without atherosclerotic CVD (ASCVD), a new study showed, suggesting this model …
CHIP Tied to HFpEF and ASCVD: What’s the Link? - Medscape
Feb 2, 2024 · First described as a cancer risk factor, growing evidence links age-related clonal hematopoiesis of indeterminate potential (CHIP) to cardiovascular disease.
Cardiovascular Risk Calculators Fail Some Patients With HIV
Feb 24, 2025 · A common CV risk factor calculator for patients with HIV underestimates risk for Black patients and women, while risk for those in low-income countries is overestimated.
Evidence Builds to Support Colchicine in Treating ASCVD
May 6, 2024 · Colchicine, a legacy drug that received a new indication in 2023 for cardiovascular disease, can treat arterial inflammation after a heart attack, a principal investigator of clinical …
Risk-Calculator Flaws Not Explained by Statin Use - Medscape
Oct 7, 2014 · In an attempt to understand why the WHS cohort had a lower 10-year risk of ASCVD than that using the ACC/AHA risk calculator, researchers asked whether patients …
LDL Not the Primary Culprit in ASCVD? - Medscape
Dec 14, 2020 · LDL cholesterol has been seen as the main offender in ASCVD, but new studies implicate other lipids, including so-called "remnant" cholesterol. An editorial, however, urges …
Statin Use Remains Low for At-Risk Patients - Medscape
Dec 4, 2023 · Expanded prescribing guidelines have not boosted statin use among patients who are at risk for atherosclerotic cardiovascular disease.
